Newsfeeds - Spark Newswire

1 minute read

Events
News

IMV To Showcase Its DPX Delivery Technology In Two Presentations At The AACR Annual Meeting 2022

Today, 6:02 PM

IMV's DPX technology elicits a coordinated anti-tumor immune response involving natural killer cells in both translational and preclinical studies Clinical data from the Company's basket study in advanced,

IMV

1 minute read

News

IMV Announced First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma

By Charles Gross

Today, 6:02 PM

IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announced a first patient dosed in the VITALIZE Phase 2B clinical trial.

IMV

1 minute read

IMV’s Basket Clinical Study Shows Promising Top Line Data In Bladder Cancer

By Vandana Singh

Today, 6:02 PM

IMV Inc (NASDAQ: IMV)

IMV

4 minute read

The Daily Biotech Pulse: Reata Plunges On Adcom Snub, AstraZeneca Antibody Cocktail Authorized For COVID-19 Prevention, NeuroSense IPO

By Shanthi Rexaline

Today, 6:02 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

AMAM

1 minute read

Events
News

IMV To Present At Piper Sandler Healthcare Conference Tuesday, Nov. 23 2021 At 11 a.m. EST

By Benzinga Newsdesk

Today, 6:02 PM

IMV Inc. (NASDAQ:IMV, TSX:IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced that

IMV

1 minute read

Watching IMV, Applied Genetic Technologies; Traders Circulate TipRanks Report ‘These 2 Penny Stocks Could Surge Over 400%, Says Wells Fargo’

By Benzinga Newsdesk

Today, 6:02 PM

https://blog.tipranks.com/these-2-penny-stocks-could-surge-over-400-says-wells-fargo/

AGTC

10 minute read

Earnings Scheduled For November 11, 2021

By Benzinga Insights

Today, 6:02 PM

Companies Reporting Before The Bell • NICE (NASDAQ:NICE) is likely to report quarterly earnings at $1.58 per share on revenue of $465.75 million.

ACHR

1 minute read

IMV Q3 EPS $(0.13) Misses $(0.09) Estimate, Sales $41.00K Down From $66.05K YoY

By Benzinga Newsdesk

Today, 6:02 PM

IMV (NASDAQ:IMV) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.09) by 44.44 percent. This is a 30 percent decrease over losses of $(0.10) per share from the same period

IMV

1 minute read

IMV’s DPX Delivery Technology To Be Showcased In 2 e-Posters At AACR-NCI-EORTC Conference On Molecular Targets And Cancer Therapeutics

By Benzinga Newsdesk

Today, 6:02 PM

IMV Inc. (NASDAQ:IMV, TSX:IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that two abstracts featuring two DPX-based

IMV

1 minute read

Cantor Fitzgerald Initiates Coverage On IMV with Overweight Rating, Announces Price Target of $4

By Benzinga Newsdesk

Today, 6:02 PM

Cantor Fitzgerald analyst Brandon Folkes initiates coverage on IMV (NASDAQ:IMV) with a Overweight rating and announces Price Target of $4.

IMV